OBJECTIVE: p53 mutations and the Ki-67 protein are frequently observed in various types of human cancer; the abnormal expression of p53 and Ki-67 in the tumor is associated with poor survival of lung cancer patients. We aimed to assess the prognostic role of immunohistochemical (IHC) expression of p53 and Ki-67 in lung adenocarcinoma tissue. METHODS: Tumor samples from 136 patients who had undergone surgical resection for lung adenocarcinoma were retrospectively evaluated for p53 and Ki-67 expression by immunohistochemistry. Associations of clinical and pathologic variables with p53 and Ki-67 were determined using the χ(2) test. After excluding two patients (follow-up loss), 134 cases were evaluated for associations between p53, Ki-67, clinical and pathologic variables, and survival by using the Cox proportional hazards regression model and Kaplan-Meier method. RESULTS: In the 136 patients, p53 was positive in 71.0% (93/131), and Ki-67 showed high in 49.2% (61/124). Unlike p53, Ki-67 was associated with male sex, smoking, and poor tumor differentiation (P=0.004, P=0.001 and P=0.006). Of these, poor tumor differentiation strongly was correlated with high level of Ki-67 expression (P=0.008). Neither p53 nor Ki-67 was associated with increased risk of death (P=0.318, P=0.053); however, age ≥60 years and lymph node involvement were significant predictors of death (P=0.039 and P=0.042). The log-rank test revealed a significant association between Ki-67 and lower survival in all patients (χ(2)=5637; P=0.018); however, the risk was limited to stage III cases (χ(2)=5.939; P=0.015). Unlike p53, patients with high level of Ki-67 expression showed lower 3-year actuarial survival than those without (log-rank test, χ(2)=4.936; P=0.026). CONCLUSIONS: IHC expression of Ki-67 in lung adenocarcinoma tissue shows stronger association with poor tumor differentiation, and negatively affects patients' survival in advanced-stage lung cancer; however, the role of p53 on patient outcome needs further study.
OBJECTIVE:p53 mutations and the Ki-67 protein are frequently observed in various types of humancancer; the abnormal expression of p53 and Ki-67 in the tumor is associated with poor survival of lung cancerpatients. We aimed to assess the prognostic role of immunohistochemical (IHC) expression of p53 and Ki-67 in lung adenocarcinoma tissue. METHODS:Tumor samples from 136 patients who had undergone surgical resection for lung adenocarcinoma were retrospectively evaluated for p53 and Ki-67 expression by immunohistochemistry. Associations of clinical and pathologic variables with p53 and Ki-67 were determined using the χ(2) test. After excluding two patients (follow-up loss), 134 cases were evaluated for associations between p53, Ki-67, clinical and pathologic variables, and survival by using the Cox proportional hazards regression model and Kaplan-Meier method. RESULTS: In the 136 patients, p53 was positive in 71.0% (93/131), and Ki-67 showed high in 49.2% (61/124). Unlike p53, Ki-67 was associated with male sex, smoking, and poor tumor differentiation (P=0.004, P=0.001 and P=0.006). Of these, poor tumor differentiation strongly was correlated with high level of Ki-67 expression (P=0.008). Neither p53 nor Ki-67 was associated with increased risk of death (P=0.318, P=0.053); however, age ≥60 years and lymph node involvement were significant predictors of death (P=0.039 and P=0.042). The log-rank test revealed a significant association between Ki-67 and lower survival in all patients (χ(2)=5637; P=0.018); however, the risk was limited to stage III cases (χ(2)=5.939; P=0.015). Unlike p53, patients with high level of Ki-67 expression showed lower 3-year actuarial survival than those without (log-rank test, χ(2)=4.936; P=0.026). CONCLUSIONS: IHC expression of Ki-67 in lung adenocarcinoma tissue shows stronger association with poor tumor differentiation, and negatively affects patients' survival in advanced-stage lung cancer; however, the role of p53 on patient outcome needs further study.
Authors: F Hommura; H Dosaka-Akita; T Mishina; M Nishi; T Kojima; H Hiroumi; S Ogura; M Shimizu; H Katoh; Y Kawakami Journal: Clin Cancer Res Date: 2000-10 Impact factor: 12.531
Authors: William D Travis; Kavita Garg; Wilbur A Franklin; Ignacio I Wistuba; Bradley Sabloff; Masayuki Noguchi; Ryutaro Kakinuma; Maureen Zakowski; Michelle Ginsberg; Robert Padera; Francine Jacobson; Bruce E Johnson; Fred Hirsch; Elizabeth Brambilla; Douglas B Flieder; Kim R Geisinger; Frederik Thunnisen; Keith Kerr; David Yankelevitz; Teri J Franks; Jeffrey R Galvin; Douglas W Henderson; Andrew G Nicholson; Philip S Hasleton; Victor Roggli; Ming-Sound Tsao; Federico Cappuzzo; Madeline Vazquez Journal: J Clin Oncol Date: 2005-05-10 Impact factor: 44.544
Authors: M Shiba; H Kohno; K Kakizawa; T Iizasa; M Otsuji; Y Saitoh; K Hiroshima; H Ohwada; T Fujisawa Journal: Cancer Date: 2000-10-01 Impact factor: 6.860
Authors: B Top; W J Mooi; S G Klaver; L Boerrigter; P Wisman; H R Elbers; S Visser; S Rodenhuis Journal: Int J Cancer Date: 1995-04-21 Impact factor: 7.396
Authors: Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal Journal: Science Date: 2014-10-10 Impact factor: 47.728
Authors: Hong Gao; Jun Yang; Lu He; Wei Wang; Yanhong Liu; Yue Hu; Meiling Ge; Jie Ding; Qing Ye Journal: Front Oncol Date: 2022-06-28 Impact factor: 5.738